ADVANCED SOLID TUMOUR
TREATMENT IN CHINA
For patients with advanced lung, liver, gastric, cervical, and other solid tumours, China offers a combination of precision diagnostics, active clinical trials, domestic drug approvals, and lower costs that makes it a clinically serious option โ not a last resort.
analyticsAt a Glance
- check_circleChina is one of the most active global destinations for solid tumour clinical trials โ with particular depth in gastric, liver, lung, and cervical cancers where Asian incidence is highest.
- check_circleDomestic approvals of targeted therapies and immunotherapy agents sometimes precede global markets โ giving international patients earlier access than available at home.
- check_circleAdvanced diagnostics including NGS, liquid biopsy, and AI-assisted pathology are standard at major Chinese cancer centres and support precision treatment planning.
- check_circleTotal treatment costs for solid tumours in China are typically 50-80% lower than in the US โ including surgery, radiation, and systemic therapy.
Why China for Solid Tumours?
China's solid tumour oncology infrastructure has been shaped by its patient population โ which includes some of the highest rates of gastric, liver, oesophageal, and lung cancer in the world. This has driven decades of concentrated clinical investment that now benefits international patients.
Trial Depth in Asian-Prevalent Cancers
For gastric cancer, liver cancer (HCC), nasopharyngeal carcinoma, and oesophageal cancer โ China has more active clinical trials than any other country. This creates access to therapies in Phase I, II, and III that are not yet available elsewhere.
Domestic Drug Approvals Ahead of Global Launch
Several targeted therapies and immunotherapy agents have received NMPA approval in China before or concurrent with FDA/EMA decisions โ including specific EGFR inhibitors, ALK inhibitors, KRAS inhibitors, Claudin 18.2-targeted agents, and HER2-targeted ADCs for gastric cancer.
Advanced Molecular Diagnostics
Comprehensive NGS, liquid biopsy, tumour mutational burden, MSI status, and HER2/PD-L1 testing are available at all major Chinese cancer centres โ often at significantly lower cost than in Western markets. Better diagnostics enable better treatment decisions.
Surgical and Interventional Expertise
China's major cancer centres have high surgical volumes for complex solid tumour resections โ hepatobiliary, pancreatic, gastric, thoracic, and gynaecological. High volume correlates with better outcomes for complex operations, and interventional oncology (TACE, microwave ablation, HIFU) is widely available.
Solid Tumours Where China Has Particular Strength
China's clinical depth varies by cancer type. These are the indications where international patients most commonly benefit from China-based options.
Lung Cancer (NSCLC and SCLC)
China has the largest lung cancer patient population in the world and the deepest EGFR, ALK, ROS1, MET, and KRAS-targeted therapy pipeline. Next-generation EGFR inhibitors for T790M and C797S resistance mutations, and EGFR-MET bispecifics, are in active Chinese trials. Immunotherapy combinations with PD-1 inhibitors are extensively studied.
Liver Cancer (HCC and Cholangiocarcinoma)
China leads globally in HCC treatment research โ with active trials for tyrosine kinase inhibitors, anti-PD-1 combinations, locoregional TACE and ablation protocols, and emerging ADC and bispecific approaches. For cholangiocarcinoma, FGFR2, IDH1/IDH2, and HER2-targeted trials are active.
Gastric and Gastro-Oesophageal Cancer
China's HER2-positive gastric cancer trial programme is among the most active in the world โ including HER2-targeted ADCs (trastuzumab deruxtecan variants), bispecific antibodies, and Claudin 18.2-targeted agents. For HER2-negative disease, PD-1 combinations and VEGFR-targeted approaches are well-studied.
Cervical Cancer
For patients with recurrent or metastatic cervical cancer after platinum-based chemotherapy, China has active PD-1-based immunotherapy trials, ADC studies (tisotumab vedotin variants and others), and access to brachytherapy expertise at specialist gynaecological oncology centres.
How CancerFax Supports Solid Tumour Patients in China
Accessing solid tumour treatment in China requires more than a hospital name โ it requires clinical matching, diagnostic review, and practical coordination.
- 1
Medical Record Review and Case Assessment
We review pathology with molecular profiling, all imaging, treatment history, and current disease status to understand which Chinese options are clinically relevant for your specific tumour type and prior treatment.
- 2
Clinical Trial or Treatment Pathway Matching
We match your case against active Chinese trials and approved treatment pathways based on cancer type, biomarkers, and prior lines of therapy.
- 3
Hospital and Specialist Identification
We identify which hospital and specialist team has the relevant expertise and active programme for your specific cancer type and treatment goal.
- 4
Pre-Travel Eligibility Confirmation
Reports are submitted for specialist review before you make any travel decision โ confirming pathway availability, eligibility, and expected timeline.
- 5
Full Coordination: Admission to Follow-Up
Documentation, translation, visa, travel, hospital communication, interpreter, and post-treatment coordination with your home oncology team.
Frequently Asked Questions
Solid Tumours in China
Which solid tumours have the most trial options in China?
Gastric cancer, lung cancer (NSCLC), liver cancer (HCC), and nasopharyngeal carcinoma have the deepest Chinese trial pipelines โ reflecting high local incidence and decades of domestic research investment. Cervical cancer, colorectal cancer, oesophageal cancer, and breast cancer also have significant trial activity. For most other solid tumour types, approved treatment pathways and some trial options are available at major Chinese cancer centres.
Can Chinese targeted therapies be brought back home?
In some cases, domestically approved Chinese targeted therapies can be continued at home through parallel import, compassionate use, or patient assistance pathways โ depending on the drug and the home country's regulations. CancerFax can advise on continuation options as part of treatment planning. Patients should never assume a drug available in China can be automatically continued at home.
Is surgery for solid tumours safe in China?
Major Chinese cancer centres have high-volume surgical programmes for complex solid tumour resections โ hepatobiliary, pancreatic, gastric, and thoracic surgery. Volume is one of the most consistent predictors of surgical outcomes for complex operations. That said, surgical outcomes depend on the specific surgeon, team, and centre โ careful centre and specialist selection is important.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Exploring Solid Tumour Treatment Options in China?
Share your pathology, imaging, and treatment history โ our clinical team will review your case and identify whether China offers a meaningful clinical or trial advantage for your specific tumour type.
This information is for patient education and navigation support only. All treatment decisions must be made in consultation with a qualified oncologist.